CN109925301A - It is a kind of to treat acne skin medicine - Google Patents

It is a kind of to treat acne skin medicine Download PDF

Info

Publication number
CN109925301A
CN109925301A CN201910335918.4A CN201910335918A CN109925301A CN 109925301 A CN109925301 A CN 109925301A CN 201910335918 A CN201910335918 A CN 201910335918A CN 109925301 A CN109925301 A CN 109925301A
Authority
CN
China
Prior art keywords
parts
acne skin
skin medicine
vitamin
metronidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910335918.4A
Other languages
Chinese (zh)
Inventor
张春喜
汪家珠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201910335918.4A priority Critical patent/CN109925301A/en
Publication of CN109925301A publication Critical patent/CN109925301A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A kind of acne skin medicine for the treatment of is made of urea, zinc oxide, metronidazole, chloramphenicol, chlorpheniramine, PINGYANPING RUANGAO, vitamin B1.It is a feature of the present invention that using the combination of a variety of Western medicine and PINGYANPING RUANGAO to realize the treatment acne skin medicine for treating acne in a short time.

Description

It is a kind of to treat acne skin medicine
Technical field
Acne skin medicine is treated the present invention relates to a kind of, and in particular to a kind for the treatment of acne skin medicine for controlling acne.
Background technique
Acne is a kind of chronic inflammatory skin of pilosebaceous unit, teenager is mainly apt to occur in, to teenager Psychology and social influence it is very big, but tended to after puberty nature mitigate or recovery from illness.Clinical manifestation is to be apt to occur in facial powder With the characteristics of the pleomorphism skin lesion such as thorn, papule, warts, tubercle, there is presently no active drugs to be treated.
Summary of the invention
Acne skin medicine is treated the purpose of the present invention is to provide a kind of, utilizes the combination of a variety of Western medicine and PINGYANPING RUANGAO To realize the treatment acne skin medicine for treating acne in a short time.
To achieve the above object, the invention provides the following technical scheme: a kind of acne skin medicine for the treatment of is by urea, oxidation Zinc, metronidazole, chloramphenicol, chlorpheniramine, PINGYANPING RUANGAO, vitamin B1 composition;
The PINGYANPING RUANGAO main ingredient includes kuh-seng, the tuber of stemona, Cortex Phellodendri.
Preferably, a kind of to treat acne skin medicine, by weight, 10-25 grams of urea, 10-25 grams of zinc oxide, metronidazole 0.6-1.2 grams, 0.4-2 grams of chloramphenicol, 0.2-0.5 grams of chlorpheniramine, 4-6 grams of PINGYANPING RUANGAO, vitamin B1 be 0.4-1 grams.
It is further preferred that 20 parts of urea, 20 parts of zinc oxide, 1.0 parts of metronidazole, 1.5 parts of chloramphenicol, 0.3 part of chlorpheniramine, 5 parts of PINGYANPING RUANGAO, vitamin B1 are 0.6 part.
It further include the sweet glycan of konjaku Pu in the dermic, the sweet glycan of konjaku Pu accounts for any one of claim 1-3 institute The 0.1-1% for the raw material total amount stated.
The sweet glycan of konjaku Pu can also be modified for thiocarbamide konjaku glucomannan, wherein the additive amount of thiocarbamide is The 10-40% of konjaku glucomannan total amount.
It further include urease inhibitor normal-butyl thiophosphoryl triamine in the dermic, the urease inhibitor accounts for right and wants Seek the 0.1-1% of the described in any item raw material total amounts of 1-3.
The urease inhibitor is dissolved using konjaku glucomannan, and forms cladded type mixture, the urase suppression The mass ratio of preparation and konjaku glucomannan is 0.5-1:2-5.
After urea, zinc oxide, metronidazole, chloramphenicol, chlorpheniramine, vitamin B1 are mixed, PINGYANPING RUANGAO is added Complete preparation.
Or after mixing urea, zinc oxide, metronidazole, chloramphenicol, chlorpheniramine, vitamin B1, addition Compound Dexamethasone Acetate is soft Cream forms emulsifiable paste;Konjaku glucomannan or the urease inhibitor normal-butyl for adding konjaku glucomannan or thiocarbamide modification are thio The konjaku glucomannan cladded type mixture of phosphoric triamide or normal-butyl thiophosphoryl triamine, can be obtained acne skin medicine.Chlorine Mycin effect: Chinese nickname D- Su Shi-(-)-N- [α-(hydroxymethyl)-beta-hydroxy-p-nitrophenyl ethyl] -2,2- dichloroacetyl Amine;(1R, 2R)-N- [α-(hydroxymethyl)-beta-hydroxy-p-nitrophenyl ethyl] -2,2- dichloro acetamide;D- (-)--1- pairs of Soviet Union Nitrobenzophenone -2- dichloroacetyl amido -1,3- propylene glycol;Chloromycetin;Left-handed-two chloroethene of Soviet Union -1- (p-nitrophenyl) -2- Acylamino- -1,3-PD belongs to broad-spectrum antibacterial antibiotic, treats one of specific medicament of anaerobic infection, belonging to bacteriostatic agent is It is fat-soluble, protein can be prevented to synthesize.
Urea effect: can be used to improve humidity of skin during smelting skin.
Metronidazole effect: there is killing effect to anaerobe, the metabolism for restoring generation in human body also has anti-anaerobism Bacterium effect, inhibits the synthesis of the DNA of bacterium, to interfere the growth of bacterium, breeding, finally causes bacterial death.
Zinc oxide effect: having the function of detoxification, promoting regeneration of tissue for astringency, keeps epidermis healing faster and better.
Chlorpheniramine effect: affected tissues amine H, receptor antagonist Liu, can to caused by antianaphylaxis telangiectasis,
The permeability of capillary is reduced, antihistamine effect is more lasting, it may have apparent central inhibitory action can be alleviated and control It treats acne skin drug and gives patient's bring pain.
Vitamin B1: water soluble vitamin is that participate in glycometabolism institute necessary, and gasification is obstructed when shortage, formed pyruvic acid,
Lactic acid accumulation, and influence human body energy supply.
PINGYANPING RUANGAO effect, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.: Aeroseb-Dex, have it is anti-inflammatory,
Anti-allergic effects can inhibit the hyperplasia of connective tissue, reduce the logical adaptive of capillary and cell membrane, reduce inflammatory exudation Amount resists histamine and the formation and release of other toxicants.
It is an advantage of the invention that acne sends out (skin adipose gland conduit dyskeratosis, infundibulum of hair follicle portion and sebaceous gland duct angle Change, lead to sebum row's remittance obstacle, sebum essence is stayed, forms powder one and pierce) Anttdisease Mechanism: sebaceous glands is opened on follicular orifice more, once hair follicle Mouth obstruction, excessive sebum are metabolized the acne propionic acid of hyper-proliferative in the stimulation and enclosed environment of the excess fat acid generated The effect of bacillus makes skin produce inflammatory reaction, and performance is from gently to being white (black) head acne, inflamed papules and warts, capsule again Swollen and tubercle, and small pox that is rubescent and suppurating is that have existing for bacterium infection.Konjaku glucomannan is utilized in the formula of this patent, Moisture is easily absorbed, the moisture in air can be also adsorbed in use process, makes have the function of moisturizing in skin surface.More into one Step, using thiocarbamide and urease inhibitor normal-butyl thiophosphoryl triamine, then with konjaku glucomannan it is compound after, delay to discharge, When other compositions being made to act on surface, release sterilization factors are delayed, during with skin contact, keep the state of skin wet Under, the sterilization factors of release act on acne again, achieve the purpose that treatment.
Specific embodiment
Patient 1: Mr. Li, and female 26 years old
Patient's oral account: there is the graininess papule to differ in size and warts and tubercle in 9 years foreface portions, treat by many years, disease Shape is increasingly severe, and nose and cheeks inflammation are significant, there is pain and tenderness, aggravation before the menstrual period, eats irritable food disease Property aggravate, come our hospital by me and be responsible for treatment, both firmly aglycosuria medical history.
Physical examination: patient face portion, forehead cheeks, are distributed symmetrically that Whiteheads are that needle point is conical to needle point size Papule is in canescence, the damage such as inflammation rash, warts, tubercle and cellulitis.
Diagnosis: acne (whelk)
Treatment: 1, systemic therapy
1.1 avoid eating irritable food, such as drinks, raw green onion, raw garlic, seafood, beef and mutton.
1.2 is oral: tetracycline, metronidazole, vitamin B1.
2, local treatment
Will " treatment acne skin medicine " (by weight, 19 grams of urea, 16 grams of zinc oxide, 0.8 gram of metronidazole, 1.2 grams of chloramphenicol, 0.4 gram of chlorpheniramine, 4 grams of PINGYANPING RUANGAO, vitamin B1 are 0.7 gram) it is coated in patient's face facial area, three times a day, treatment one Zhou Hou, further consultation, patient symptom are relieved, and running sore absorbs obvious, tubercle and reduces, and red and swollen obvious disappearance without pain, rear phone returns It visits, patient continues local treatment one week, is almost recovered.
Patient 2: Mr. Wang male 19 years old
Patient's oral account: there is the graininess papule to differ in size, running sore, tubercle in five years ago face, and face has slight once in a while Wound, it is increasingly severe by many years treatment disease without alleviation, it is significant with forehead and cheeks inflammation, there are pain and tenderness, eats irritation Food characteristic of disease aggravates, no heredity medication history, diabetic history.
Physical examination: patient face portion, especially forehead, cheeks and lower jaw part are distributed symmetrically, and are needle from (black) head acne The damage of the pleomorphism such as sharp size cone disease rash, abscess sinus and tumour.
Diagnosis: acne (whelk)
Treatment: 1, systemic therapy
1.1 avoid eating irritable food, such as drinks, raw green onion, raw garlic, seafood, beef and mutton.
1.2 is oral: tetracycline, vitamin B1.
1.3 clearing heat and detoxicating.
2, local treatment
Will " treatment acne skin medicine " (by weight, 15 grams of urea, 13 grams of zinc oxide, 0.8 gram of metronidazole, 0.7 gram of chloramphenicol, 0.5 gram of chlorpheniramine, 6 grams of PINGYANPING RUANGAO, vitamin B1 are 1 gram, the modified konjaku glucomannan of 0.2g thiocarbamide, wherein thiocarbamide Additive amount be konjaku glucomannan total amount 20%) be coated in patient's face facial area, three times a day, after one week treatment, further consultation, Patient symptom is relieved, and blackhead significantly reduces, and red and swollen obvious disappearance without pain is itched without disturbing, rear call-on back by phone, patient's continuation office Portion is treated 10 days, is almost recovered.
3 Zhang of patient male 21 years old
Patient oral account: there is the graininess papule to differ in size, running sore, tubercle in five years ago facial area, by many years treatment symptom without Substantially reduced, increasingly severe, especially forehead, cheeks inflammation is significant and touches, and eats irritable food aggravation.
Physical examination: patient face portion, especially forehead, cheek are distributed symmetrically white (black) head acne, papule, skin pore Increase, abscess, local organization recess has formed scar
Diagnosis: acne (whelk)
Treatment: 1, systemic therapy
1.1 avoid eating irritable food, such as drinks, raw green onion, raw garlic, seafood, beef and mutton.
1.2 is oral: tetracycline, metronidazole, vitamin B1.
1.3 clearing heat and detoxicating.
2, local treatment
Will " treatment acne skin medicine " (by weight, 21 grams of urea, 20 grams of zinc oxide, 1.2 grams of metronidazole, 1.9 grams of chloramphenicol, 0.5 gram of chlorpheniramine, 5 grams of PINGYANPING RUANGAO, vitamin B1 are 0.8 gram, normal-butyl thiophosphoryl triamine 0.15g) it is coated in patient Face facial area, three times a day, after one week treatment, further consultation, patient symptom is relieved, hair pore shrinkage, and redness disappears, and tubercle is obvious It reduces, rear call-on back by phone, patient continues local treatment 10 days, is almost recovered.
Patient 4: it is remaining so-and-so female 19 years old
Patient's oral account: there is the graininess papule to differ in size, running sore, tubercle in 4 years foreface portions, and two thats can bitterly, by for many years Treatment, it is increasingly severe, it is especially significant with cheeks inflammation, there is tenderness, eats irritable food aggravation, aglycosuria medical history.
Physical examination: there are the redness to differ in size, pustular tubercle in patient face portion, especially forehead, cheeks portion, are in latent menstruation Color, quality is harder, light to press pain obvious.
Diagnosis: acne (whelk)
Treatment: 1, systemic therapy
1.1 avoid eating irritable food, such as drinks, raw green onion, raw garlic, seafood, beef and mutton.
1.2 is oral: tetracycline, metronidazole, vitamin B1.
1.3 clearing heat and detoxicating, dampness removings.
2, local treatment
Will " treatment acne skin medicine " (by weight, 17 grams of urea, 21 grams of zinc oxide, 0.9 gram of metronidazole, 0.7 gram of chloramphenicol, 0.2 gram of chlorpheniramine, 6 grams of PINGYANPING RUANGAO, vitamin B1 are 0.5 gram, the konjaku glucomannan packet of normal-butyl thiophosphoryl triamine Type mixture is covered, wherein the mass ratio of normal-butyl thiophosphoryl triamine and konjaku glucomannan is 1:2) it is coated in patient's face face Portion, three times a day, after one week treatment, further consultation, patient symptom is relieved, red and swollen to disappear, without pain, rear call-on back by phone, patient After continuing local treatment two weeks, it is almost recovered.
The above patient is more serious acne (whelk) patient, and systemic therapy is general treatment mode, but former It does not play a role in therapeutic process, and after plus this patent product, achieve preferable effect.

Claims (9)

1. a kind of treat acne skin medicine, it is characterised in that: the treatment acne skin medicine is by urea, zinc oxide, metronidazole, chlorine Mycin, chlorpheniramine, PINGYANPING RUANGAO, vitamin B1 composition.
2. treating acne skin medicine according to claim 1, it is characterised in that: by weight, 10-25 parts of urea, zinc oxide 10-25 parts, 0.6-1.2 parts of metronidazole, 0.4-2 parts of chloramphenicol, 0.2-0.5 parts of chlorpheniramine, 4-6 parts of PINGYANPING RUANGAO, vitamin B1 is 0.4-1 parts.
3. treating acne skin medicine according to claim 1, it is characterised in that: by weight, 20 parts of urea, zinc oxide 20 Part, 1.0 parts of metronidazole, 1.5 parts of chloramphenicol, 0.3 part of chlorpheniramine, 5 parts of PINGYANPING RUANGAO, vitamin B1 are 0.6 part.
4. treating acne skin medicine according to claim 1, it is characterised in that: further include konjaku Pu Ganju in the dermic Sugar, the sweet glycan of konjaku Pu account for the 0.1-1% of the described in any item raw material total amounts of claim 1-3.
5. treatment acne skin medicine according to claim 4, it is characterised in that: the sweet glycan of konjaku Pu can also be The modified konjaku glucomannan of thiocarbamide, wherein the additive amount of thiocarbamide is the 10-40% of konjaku glucomannan total amount.
6. according to claim 1 treat acne skin medicine, it is characterised in that: further include in the dermic urease inhibitor just Butylthiophosphoric triamide, the urease inhibitor account for the 0.1-1% of the described in any item raw material total amounts of claim 1-3.
7. treating acne skin medicine according to claim 4, it is characterised in that: the urease inhibitor uses Amorphophallus rivieri glucomannan Glycan dissolution, and cladded type mixture is formed, the mass ratio of the urease inhibitor and konjaku glucomannan is 0.5-1:2- 5。
8. it is according to claim 1-3 treatment acne skin medicine preparation method, it is characterised in that: by urea, After zinc oxide, metronidazole, chloramphenicol, chlorpheniramine, vitamin B1 mixing, preparation is can be completed in addition PINGYANPING RUANGAO.
9. according to claim 4-7 treat acne skin medicine preparation method, it is characterised in that: by urea, zinc oxide, After metronidazole, chloramphenicol, chlorpheniramine, vitamin B1 mixing, PINGYANPING RUANGAO is added, emulsifiable paste is formed;
Add the konjaku glucomannan or urease inhibitor normal-butyl thiophosphoryl triamine that konjaku glucomannan or thiocarbamide are modified Or the konjaku glucomannan cladded type mixture of normal-butyl thiophosphoryl triamine, acne skin medicine can be obtained.
CN201910335918.4A 2019-04-24 2019-04-24 It is a kind of to treat acne skin medicine Pending CN109925301A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910335918.4A CN109925301A (en) 2019-04-24 2019-04-24 It is a kind of to treat acne skin medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910335918.4A CN109925301A (en) 2019-04-24 2019-04-24 It is a kind of to treat acne skin medicine

Publications (1)

Publication Number Publication Date
CN109925301A true CN109925301A (en) 2019-06-25

Family

ID=66990898

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910335918.4A Pending CN109925301A (en) 2019-04-24 2019-04-24 It is a kind of to treat acne skin medicine

Country Status (1)

Country Link
CN (1) CN109925301A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101264099A (en) * 2008-04-24 2008-09-17 郑华奇 Medicaments for treating acne rosacea, comedo and acne

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101264099A (en) * 2008-04-24 2008-09-17 郑华奇 Medicaments for treating acne rosacea, comedo and acne

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
史丽英: "魔芋葡甘聚糖的研究利用", 《河南科技》 *
徐国芳: "痤疮面膜治疗痤疮近期疗效观察", 《中国皮肤性病学杂志》 *
闫章存: "复方地塞米松霜的研制及临床应用", 《药学情报通讯》 *

Similar Documents

Publication Publication Date Title
US5554361A (en) Processed product for skin and hair treatment
CN108135972B (en) Application of mussel mucin product in treating and preventing melanin-related diseases
TWI841523B (en) Methods of treating and/or preventing actinic keratosis
NZ223558A (en) Acne treatment composition
AU2022275473A1 (en) Ammonia oxidizing bacteria for treatment of acne
RU2762754C2 (en) Composition applicable in prevention and/or treatment of oral and gastrointestinal mucositis induced by oncological treatment
JP2022510377A (en) Composition for treatment of the condition
WO2004100923A1 (en) The composition for external use by percutaneous administration
CN109925301A (en) It is a kind of to treat acne skin medicine
CN107961232B (en) Pharmaceutical formulations and uses thereof
CN102697835B (en) The topical agent for the treatment of disease of skin
CN105031254B (en) A kind of paste and preparation method thereof for treating dermatitis
WO2015059572A1 (en) A method for topically treating actinic keratosis with ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
JP2022169626A (en) Combination therapy for treatment of skin diseases
Dave et al. Low dose isotretinoin for pigmented post‐varicella scars.
CN110393772A (en) A kind of pharmaceutical composition and preparation method promoting radiotherapy patient skin wound healing
CN110403891A (en) A kind of Chinese herbal toothpaste with oral health effect
Fox Photographic Atlas of the Diseases of the Skin
CN109172722A (en) A kind of composition that treating acne and its application
RU2805929C2 (en) Methods for treating and/or preventing actinic keratosis
Whitaker et al. Necrotizing Soft Tissue Infection Complicating Levamisole-Induced Vasculitis
Land Analysis of the Curative Effect from the Injection of Sclerosing Agent in 1,000 Patients with Vascular Abnormalities
WO2024173775A1 (en) Dietary supplement for managing stress-induced inflammatory skin disorders
Lynch et al. 18125 Evaluation of the efficacy and tolerability of a trichloroacetic acid facial peel and post-peel masque
Harris et al. 18087 Clinical and histologic manifestations of ecthyma contagiosum in west Texas farmers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination